These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 22768589)

  • 1. [Fixed dose of combination of pioglitazone/metformin].
    Ugi S; Maegawa H
    Nihon Rinsho; 2012 May; 70 Suppl 3():627-32. PubMed ID: 22768589
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone + metformin: new drug. A combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17724835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 5. Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).
    Karamanos B; Thanopoulou A; Drossinos V; Charalampidou E; Sourmeli S; Archimandritis A;
    Curr Med Res Opin; 2011 Feb; 27(2):303-13. PubMed ID: 21142615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet.
    Karim A; Slater M; Bradford D; Schwartz L; Laurent A
    J Clin Pharmacol; 2007 Jan; 47(1):48-55. PubMed ID: 17192501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.
    Liao L; Yang M; Qiu LL; Mou YR; Zhao JJ; Dong JJ
    Chin Med J (Engl); 2010 Dec; 123(24):3684-8. PubMed ID: 22166651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
    Derosa G; Tinelli C; Maffioli P
    Diabetes Obes Metab; 2009 Dec; 11(12):1091-9. PubMed ID: 19765050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
    MMW Fortschr Med; 2004 Jul; 146(29-30):48-9. PubMed ID: 15540563
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
    Lester JW; Fernandes AW
    Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
    Meshram DM; Langade DG; Kinagi SB; Naikwadi AA; Morye V; Chopra D
    J Indian Med Assoc; 2005 Aug; 103(8):447-50. PubMed ID: 16363204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 2 diabetes. Use of fixed-dose oral combinations.
    Bell DS; Wyne KL
    Postgrad Med; 2006; 119(2):8-14. PubMed ID: 16961047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.